Odefsey (Emtricitabine/Rilpivirine/Tenofovir alafenamide) for HIV

Overview
Odefsey is a prescription drug approved by the Food and Drug Administration (FDA) as a complete regimen to treat HIV-1 infection in people 12 years and older. Odefsey is a combination drug composed of Emtricitabine, Rilpivirine, and Tenofovir alafenamide, which are also known respectively by the abbreviations FTC, R, and TAF. Emtricitabine and Tenofovir alafenamide are both antiretroviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. Rilpivirine is an antiretroviral drug of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. All three drugs are believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Odefsey is taken once daily. Odefsey comes in tablet form.

Side effects
The FDA-approved label for Odefsey lists common side effects including headache, insomnia, depressive disorders, and nausea. Rare but serious side effects listed for Odefsey include severe skin and hypersensitivity reactions, kidney and liver problems, changes in amount or location of body fat, bone loss, and immune reconstitution syndrome (an inflammatory disorder).

For more details about this treatment, visit:

Odefsey – Gilead